182 related articles for article (PubMed ID: 12766122)
1. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.
Wysowski DK; Armstrong G; Governale L
Diabetes Care; 2003 Jun; 26(6):1852-5. PubMed ID: 12766122
[TBL] [Abstract][Full Text] [Related]
2. Use of antidiabetic drugs in the U.S., 2003-2012.
Hampp C; Borders-Hemphill V; Moeny DG; Wysowski DK
Diabetes Care; 2014; 37(5):1367-74. PubMed ID: 24623020
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. FDA safety actions for antidiabetic drugs marketed in the US, 1980-2015.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Risk Saf Med; 2016; 28(4):197-211. PubMed ID: 28582876
[TBL] [Abstract][Full Text] [Related]
5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
6. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
7. Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study.
Liu CH; Chen ST; Chang CH; Chuang LM; Lai MS
Public Health; 2017 Nov; 152():20-27. PubMed ID: 28719837
[TBL] [Abstract][Full Text] [Related]
8. Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan.
Chu CH; Hsu CC; Lin SY; Chuang LM; Liu JS; Tu ST
J Formos Med Assoc; 2019 Nov; 118 Suppl 2():S74-S82. PubMed ID: 31248659
[TBL] [Abstract][Full Text] [Related]
9. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes.
Cohen FJ; Neslusan CA; Conklin JE; Song X
Diabetes Care; 2003 Jun; 26(6):1847-51. PubMed ID: 12766121
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacoepidemiology of diabetes: assessment of good use of oral antidiabetic drugs].
Vauzelle-Kervroëdan F; Javoy F; Forhan A; Fender P; Eschwège E
Diabetes Metab; 2000 Sep; 26 Suppl 6():63-8. PubMed ID: 11011241
[TBL] [Abstract][Full Text] [Related]
11. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
Clemens KK; Liu K; Shariff S; Schernthaner G; Tangri N; Garg AX
Diabetes Obes Metab; 2016 Jun; 18(6):607-14. PubMed ID: 26939711
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic treatment of type 2 diabetes: oral medications.
Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
Ann Pharmacother; 2015 May; 49(5):540-56. PubMed ID: 25667196
[TBL] [Abstract][Full Text] [Related]
13. Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015.
Lunger L; Melmer A; Oberaigner W; Leo M; Juchum M; Pölzl K; Gänzer J; Innerebner M; Eisendle E; Beck G; Kathrein H; Heindl B; Schönherr HR; Lechleitner M; Tilg H; Ebenbichler C
Wien Klin Wochenschr; 2017 Jan; 129(1-2):46-51. PubMed ID: 27909794
[TBL] [Abstract][Full Text] [Related]
14. [Antidiabetic drugs prescription patterns among a group of patients in Colombia].
Machado Alba JE; Moncada Escobar JC; Mesa Escobar G
Rev Panam Salud Publica; 2007 Aug; 22(2):124-31. PubMed ID: 17976279
[TBL] [Abstract][Full Text] [Related]
15. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Johnson JA; Majumdar SR; Simpson SH; Toth EL
Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic treatment of type 2 diabetes: injectable medications.
Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
Ann Pharmacother; 2015 Jun; 49(6):700-14. PubMed ID: 25802244
[TBL] [Abstract][Full Text] [Related]
18. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
19. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
20. Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.
Chen HY; Chiu PY; Chang CJ; Tsai LL; Huang YL; Hsu JC
Clin Drug Investig; 2018 Dec; 38(12):1125-1133. PubMed ID: 30219950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
